Bisoprolol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Bisoprolol: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Bisoprolol is a beta-1 selective blocker, originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant renovascular hypertension, but there are currently 0 clinical trials and 0 publications supporting this specific prediction. The signal is computational only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (taken from the knowledge-graph indication record, as no approved indication text is listed for the Singapore licences) |
| Predicted New Indication | Malignant renovascular hypertension |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, bisoprolol is a beta-1 selective blocker. It lowers heart rate and cardiac output and reduces renin release. Its efficacy in hypertension is established, and renin suppression could plausibly help in renovascular hypertension, where the renin-angiotensin system is often overactive.
This is a class-level inference only. Malignant renovascular hypertension is closely related to the existing hypertension indication, so the prediction is closer to an extension of the current label than true repurposing. The high TxGNN score reflects model confidence, not clinical proof. Malignant hypertension is also usually managed with other first-line agents.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Bisoprolol has 20 valid single-ingredient registrations, all oral tablets (film-coated or plain). No approved indication text is listed for these products. Main authorisations:
| Authorization Number | Product Name | Dosage Form | Strength |
|---|---|---|---|
| SIN01039P | CONCOR 5 Tablet | Film-coated tablet | 5 mg |
| SIN11349P | CONCOR Tablet | Film-coated tablet | 2.5 mg |
| SIN12568P | BISOHEXAL Tablet | Film-coated tablet | 5 mg |
| SIN15399P | COSYREL Film-coated Tablet | Film-coated tablet | 5 mg / 10 mg |
| SIN16300P | BISODAC 2.5 Film-coated Tablets | Film-coated tablet | 2.5 mg |
Safety Considerations
- Conditions flagged in the knowledge graph (not label text): The knowledge graph links bisoprolol with the following conditions as contraindication-related. They include asthma, diabetes mellitus and diabetic ketoacidosis, liver disease, kidney disease and anuria, pancreatitis, gout, psoriasis, systemic lupus erythematosus, myasthenia gravis, hepatic encephalopathy, anxiety and related mood disorders, and several metabolic disorders (potassium deficiency, hypercalcaemia, hyperparathyroidism). These are not confirmed by the package insert and should be checked against it.
- Drug Interactions: The interaction screen returned 100 interacting drugs. Examples of moderate-level interactions include epinephrine, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), anticholinergics (atropine, hyoscyamine, methscopolamine), bupropion, morphine, acetohexamide and calcium salts. Minor-level examples include aspirin and aluminium hydroxide.
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no trials or publications. The condition largely overlaps with bisoprolol's existing hypertension use, so it adds little as a repurposing opportunity. Malignant hypertension is also typically treated with other agents.
To proceed, the following is needed:
- Parsed package insert warnings and contraindications from the HSA website
- Detailed mechanism of action data from DrugBank
- Any clinical or observational evidence in renovascular or malignant hypertension
- Review of other predictions: of the other predicted indications, chronic pulmonary heart disease has the strongest support. It has a completed Phase 3 trial of bisoprolol in COPD (NCT03917914, n=280) and randomised trial reports (BICS, 2024–2025). That evidence is in COPD rather than cor pulmonale itself, so trial outcomes should be reviewed directly. Several other predictions (pulmonary hypertension, Prinzmetal angina, cerebrovascular disorder) have only preclinical or indirect evidence, and beta-blockers may be unsuitable in pulmonary arterial hypertension.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.